PDCD1 and hepatocellular carcinoma: In a phase III trial, 413 patients with advanced HCC who had not responded to sorafenib were assigned to receive a placebo (n = 135) or 200 mg of pembrolizumab (anti-PD-1) (n = 278) on day 1 of every 21-day cycle for a maximum of 35 cycles [28].